Introduction
Current gene therapy approaches involve delivery of a therapeutic gene by viral or nonviral vectors, which are often difficult to target to specific populations of cells and give a short duration of gene expression. Sitespecific gene repair of a mutated gene at its normal chromosomal location would be an alternative strategy for gene therapy. The corrected gene would be regulated by its endogenous promoter, and expressed at physiological levels in the appropriate cell type. By targeting gene repair to populations of stem cells, it is possible that long-term correction might be achieved through clonal expansion. The feasibility of somatic cell gene targeting has been demonstrated using RNA:DNA chimaeric oligonucleotides (RDOs) or single-stranded DNA oligonucleotides (ODN) in vitro [1] [2] [3] [4] [5] [6] and in vivo. [6] [7] [8] [9] [10] Gene repair has also been reported in vivo, using short DNA fragments in the lung 11 and muscle. 9, 12 It is difficult to compare the efficiency of in vivo gene repair methods used by different groups, because each experimental approach is very different. Methods of delivery can vary, for example, intravenous 8 and intraperitoneal 13 approaches have both been reported to target the liver. There are also variations in the loci of genes targeted by these approaches and in their levels of transcription, both of which may impinge upon the success of gene repair. 8 A mouse model bearing a mutated reporter gene such as LacZ allows sensitive detection of somatic gene repair and identification of cell types successfully targeted. A suitable locus for expression of such a reporter would be the Rosa26 locus, which directs ubiquitous expression in the embryo and the adult mouse. 14 The Rosa26 locus was originally identified by a retroviral gene trap event in mouse embryonic stem (ES) cells. 15 This locus has been used to monitor CRE- 16, 17 or FLP-18 mediated recombination events. We therefore targeted the Rosa26 locus with the mutated LacZ Glu461Lys gene to generate a reporter mouse and used this mouse to study the ability of single-stranded oligonucleotides to mediate chromosomal gene repair, which would be detected by restoration of functional b-galactosidase (b-gal) activity.
Results

Generation of the Gtrosa26 tm1Col reporter mouse
A reporter mouse for the detection of somatic gene repair events was generated by recreating the Rosa26 insertion event in mouse ES cells using a LacZ gene with a 1 basepair missense mutation. This mutation causes a Glu to Lys amino-acid change and abrogates b-galactosidase activity. 19 This mutation has been used by others to study gene repair in vitro. 3, 4, 20 ES cells (129S6Sv/Ev strain) were electroporated with the linearized pR26M1bgeo vector ( Figure 1 ) and correctly targeted clones identified by Southern blot (Figure 1c ). Of 47 clones analysed, nine had a single copy of the bgeo M1 cassette correctly targeted to the Rosa26 locus. As expected, none of these targeted clones showed functional b-gal activity although they expressed similar amounts of b-gal protein to the original Rosa26 ES line (Figure 2a ). Mice were generated from two independently targeted ES clones and both lines gave identical results.
Mutant bgeo expression in the Gtrosa26 tm1Col mouse
To confirm that the mutated bGEO protein was ubiquitously expressed from the Rosa26 locus, the presence of the 143 kDa fusion protein was assessed by immunoprecipitation and western blotting. Expression was analysed in ES cells (Figure 2a ), primary embryonic fibroblasts and tissues (Figure 2b ) from the Gtrosa26 tm1Col mice, including the brain, heart, lung, spleen, liver, kidney and skeletal muscle. The two protein bands seen in many of the western blots do not appear to be caused by protease activity, as increasing the concentration of protease inhibitors in the lysis buffer and immunoprecipitation reaction had no effect on these bands. Tissues (including liver, Figure 3 ) from the Gtrosa26 tm1Col mouse were assessed for b-gal activity and none was observed apart from background in the medulla of the kidney and bile duct. This was also observed in wild-type mice (not shown). In contrast, strong b-gal activity was detected with high sensitivity in Gtrosa26 heterozygote liver ( Figure 3 ) and in other organs including the kidney, brain, lung, heart and skeletal muscle. bgeo, were transfected with a 35 base antisense oligonucleotide and stained for b-gal activity 48 h after transfection, using a protocol as previously described. 5 Very few blue cells were observed. The repair frequency was estimated to be 9 Â 10 À5 of the total number of cells, although some experiments gave no gene repair.
Attempts to achieve gene repair in vivo
To assess gene repair in vivo, intramuscular, intravenous and intraperitoneal routes were used to deliver a 35 base antisense oligonucleotide or an RDO used in our previous in vitro study. 5 A LacZ or luciferase expression plasmid was used to confirm successful gene delivery to each tissue.
Attempts to achieve gene repair in vivo were not successful. Table 1 summarizes the in vivo gene repair approaches tested. Each combination was tested on a minimum of six mice. As a positive control for each delivery method, a LacZ plasmid (pCMVb) or a LacZ-based mouse for detection of gene repair events HD Nickerson and WH Colledge luciferase plasmid (pVR1223) was delivered under identical conditions to wild-type mice of the same age. PBS only negative controls gave no b-gal activity in whole mount or cryosection staining, and luciferase activity below 3 Â 10 À3 RLU/mg protein. Organs giving 40.1 RLU/mg protein were deemed positive for luciferase expression. Delivery of ODN gave no indication of successful gene repair, as no b-gal activity was detected in staining of whole-mount organs or cryosections. Failure to detect gene repair events was not due to the compromised integrity of the ODN as this oligonucleotide continued to give gene repair events on cell lines in culture.
Discussion
We have generated a transgenic mouse line with widespread expression of a mutated bgeo gene, which has been used previously to detect gene repair in vitro. The mice are a valuable resource to evaluate gene repair strategies in vivo and for determining precisely which organ systems are amenable to this approach. While the rate of gene repair is likely to vary between different loci, the Gtrosa26 tm1Col mice provide a useful tool for assessing the overall efficiency of gene repair at a specific site within the genome. They can also be used as a source of primary cells for in vitro assessment of gene repair protocols.
Gene repair was observed at very low levels (9 Â 10 À5 ) in ES cells heterozygous for the Gtrosa26 tm1Col insertion. Nevertheless, this demonstrates that the mutated bgeo can be repaired using a 35 base antisense oligonucleotide. This low level of gene repair probably reflects the low transfection efficiency associated with ES cells (approximately 1-5%) and previous work has shown ES cells to have very low levels of gene repair activity. 5, 21 In addition, ES cells have an intrinsically lower rate of mutation frequency compared to somatic cells, which might also influence gene repair frequencies. 22 The lack of detectable gene repair events in these mice is probably due to the inefficiency of gene delivery in vivo. In our previous study, the frequency of cells showing gene repair ranged from 5 Â 10 À6 to 2 Â 10
À3
even when nearly all the cells were transfected, such as with HEK293T. 5 Even if gene repair frequencies are corrected to a theoretical transfection efficiency of 100%, the highest level of gene repair would still only be around 2.5 Â 10 À3 . Assuming that this efficiency of gene repair could be achieved in vivo, then around 400 cells would have to be transfected to obtain one repaired cell. Unfortunately, the levels of gene delivery seen in this study were too low to allow gene repair to be easily detected in vivo. We used a Luciferase or a LacZ reporter plasmid to monitor the efficiency of each delivery procedure in vivo. Gene delivery efficiencies were generally low (Table 1) , although this might be an underestimate of the number of cells that take up the antisense oligonucleotide. It is known that short DNA molecules can access the nucleus more efficiently than plasmid molecules, which become sequested by cytoplasmic elements. 23, 24 In cell culture, the transfection efficiency of a LacZ plasmid was similar to the number of cells that took up a fluorescently labelled oligonucleotide.
Another possible reason why we have not yet detected gene repair events in vivo is that the level of b-gal expression from the corrected bgeo gene is not sufficiently high to allow visualization. We believe this to be very unlikely since expression of the mutated bgeo gene is driven from the strong, constitutively active Rosa26 promoter and the western blot analysis of tissues from the Gtrosa26 tm1Col mice indicates that the amount of mutated b-gal protein is similar to that expressed by the Rosa26 reporter mice.
Several transgenic rodent lines have been generated to detect gene mutation events in vivo. These include the Big Bluet mouse, which carries copies of the LacI gene, 25 and MutaMouset, which has several copies of the LacZ gene, 26 both as part of lambda shuttle vectors. These genes can be rescued from genomic DNA by packaging into bacteriophage lambda and mutation rates quantified by the ratio of white to blue (for LacI) or blue to white (for LacZ) plaques after infection of an appropriate strain of ) of these reporter genes is around 10-fold higher than at endogenous loci such as Hprt or Aprt (1 Â 10 À6 ), probably reflecting the higher copy number (50-80 copies) of the reporter genes. 27 Interestingly, the in vivo mutation rates of all these loci can be increased to around the same level (1 Â 10
À4
) by administration of alkylating agents such as ENU to the mice. Thus, it should be possible to identify a b-gal-positive cell for every 10 000 cells after treatment with N-ethyl-N-nitrosourea (ENU) in our mice and these experiments are ongoing. The low rate of mutation at a single gene locus in vivo means that spontaneous activation of the mutated bgeo gene will be a rare event, occurring approximately in one cell per million.
It is also possible that we failed to detect gene repair in muscle because of immune responses to corrected b-gal and elimination of fibres. Expression of b-gal in mouse muscle can elicit inflammatory responses with tissue infiltration by macrophages and T lymphocytes. 28 Inflammatory responses are unlikely to account for the lack of expression in our system, however, as the mice will be immunotolerant to the mutant b-gal protein which differs by only one amino acid from any corrected protein. Moreover, our ability to detect blue muscle fibres after delivery of the control LacZ reporter plasmid indicates that immune responses did not eliminate expression of the wild-type b-gal.
Although we could not demonstrate gene repair in vivo, others have reported high frequencies of gene repair using RDO molecules similar to those used in this study. For example, Tagalakis et al 13 delivered chimaeraplasts complexed with ExGen500 to the liver via intraperitoneal injection, producing approximately 25% conversion of ApoE2 to ApoE3 as assessed by PCR analysis of DNA extracted from liver. Conversion efficiencies in individual animals ranged from 3 to 34%. In cell culture, they demonstrated secretion of ApoE3 protein; however, this was not shown in vivo. This makes it difficult to assess whether the in vivo data may have originated from a PCR artefact. We used a similar delivery method for an RDO or a single-stranded DNA oligonucleotide, neither of which produced observable gene repair in vivo.
Another study by Kren et al 8 reports 20% correction of the UGT1A1 genetic defect in Gunn rat liver. RDO was delivered by tail vein injection either naked or encapsulated in liposomes or polyethylenamine (PEI). Livers were analysed by PCR, Southern and western blotting, and the presence of the UGT1A1 corrected gene and protein confirmed. In addition to these data, a significant reduction in serum bilirubin levels was maintained for up to 10 months after in vivo administration of RDO, when compared to control animals. It is hard to see how these data could reflect anything other than high levels of gene repair in vivo. This suggests either a much higher level of gene delivery by Kren and colleagues, a species difference or perhaps a difference in the quality of oligonucleotide synthesis.
One factor to be considered when evaluating this technology for potential clinical use is the sourcing, cost and quality control of the repair oligonucleotides or fragments. This is particularly relevant when considering the RDOs. Other groups have reported limited success in gene targeting with these oligonucleotides, 29 and it is likely that others have attempted to use this technology but failures have not been reported in the literature. Groups advocating RDOs as a strategy for gene repair believe that this may be due to differences in the cell type, target locus or quality control in oligonucleotide synthesis. It is difficult to find a supplier for RDOs; companies that provided material for some of the successful studies 8 are no longer providing this service. Chromosomal targeting has not been achieved with an RDO synthesized on two separate occasions with an identical sequence and to the specification outlined in the literature. This suggests that lack of reproducibility in synthesis conditions, rather than the target mutation itself, is responsible for the difference observed in experimental outcome. Moreover, in our hands, singlestranded DNA oligonucleotides have produced very consistent results supporting recent data from the laboratory of Yoon. 30, 31 When correcting the tyrosinase gene in albino mouse melanocytes, ODNs produced pigmented cells, indicating gene repair in 60% of experiments, while RDOs produced pigmented cells in only 10%.
The improvement of oligonucleotide delivery is critical to the advancement of the field of gene repair, and also of other technologies such as antisense. One group have tried to ensure delivery by microinjection of small DNA fragments into human lymphocytes to convert the sickle cell mutation in the b-globin gene. 32 This approach, however, is both costly, labour intensive and only suited to ex vivo applications such as manipulation of defined stem cells. It has been shown that short peptides such as an integrin-targeting RGD peptide are capable of enhancing gene delivery of plasmid DNA, perhaps by receptor-mediated endocytosis. 33, 34 This approach may be useful in delivering an oligonucleotide or short DNA fragment. Also, studies in our laboratory have shown that the addition of the steroid hormone b-estradiol can enhance in vitro gene delivery of a luciferase reporter gene to polarized epithelial cells 900-fold and delivery to mouse airway cells eight-fold. 35 Creative approaches to overcoming barriers to gene delivery in vivo will be the key to the successful application of gene repair as a form of gene therapy.
Experimental protocol Generation of the targeting vector pR26
M1 bgeo
The targeting vector pR26
M1
bgeo was generated by megaprimer PCR with Herculase polymerase (Stratagene, UK). The first PCR generated a 290 bp megaprimer with a G to A mutation at position 1651 of the bgeo gene (primers: LacZmut1rev TAGCGCCGTGGCCTGATTAT TCCCCAGCGACCAGATGAT, LacZRV for CCTCTGCAT GGTCAGGTCATGGATGAGCAG, cycle: 951C, 5 min (941C, 30 s; 631C, 30 s; 721C, 1 min) Â 40 cycles, 721C, 5 min. This megaprimer was gel purified (QiaQUICK, Qiagen, UK) and used with the LacZRIrev primer (CAGCTGGAATTCCGCCGATAC) to generate a larger 1.9 kb fragment containing the bgeo mutation. This was cloned using unique EcoRI and EcoRV sites into pSAbgeo (a generous gift from Professor Phillipe Soriano, Fred Hutchinson Cancer Research Centre, Seattle, USA). The resulting mutant bgeo cassette was ligated into the XbaI LacZ-based mouse for detection of gene repair events HD Nickerson and WH Colledge site of the pR26-1 targeting vector, which has 5.5 kb of homology to the Rosa26 locus (also a gift from Professor Soriano). The targeting vector was linearized at a unique KpnI site outside the region of homology and electroporated into CCB ES cells. Targeted clones were identified by Southern blotting using probes to the Rosa26 5 0 flank.
Detection of b-gal by western blotting
Tissues were lysed in cold IPH buffer (0.5% NP40, 50 mM Tris-HCL (pH 8), 150 mM NaCl, 5 mM EDTA+protease inhibitor cocktail (Roche)) for 20 min on ice. Lysates were spun for 1 min at 13 000 g to pellet debris and the supernatant taken for immunoprecipitation with 1/1000 mouse monoclonal anti-b-gal (Catalogue number Z378, Promega, UK) and mixed by rotation at 41C overnight.
Immunoprecipitates were bound to protein A/protein G sepharose beads (Amersham Biosciences, UK) with mixing at 41C for 2 h. Beads were pelleted and washed three times with cold IPH buffer. In all, 15 ml of 4 Â Laemmli buffer was added to the washed pellet and the precipitates boiled for 5 min prior to loading on a 7.5% polyacrylamide gel. Gels were transferred onto Amersham ECL nitrocellulose membrane, using a semidry blotter (BioRad, UK) for 1 h at 100 mA constant current.
Filters were blocked for 1 h at room temperature in PBS/0.1% Tween20 and probed at 41C overnight with 1/10 000 mouse monoclonal anti-b-gal (G3781 Promega). Blots were washed and then probed for 45 min with 1/60 000 Sigma anti-mouse HRP, washed, and the ECL plus system (Amersham Biosciences) was used for visualization.
Genotyping
Genotyping was performed using Qiagen Taq 
Plasmids and oligonucleotides
The 35 base antisense oligonucleotide (TTAGCGCCGT GGCCTGATTCATTC CCCAGCGACCA) had three phosphorothioate links at the 5 0 and 3 0 ends, and was synthesized and HPLC purified by New England Biolabs, USA. The LZ 68 base RDO oligonucleotide (upper case denotes DNA residues, lower case denotes RNA residues TCGCTGGGGAATGAAT CAGGCCACGTTTTcguggccugaTTCATuccccagcgaGCGCG TTTTCGCGC) was synthesized and HPLC purified by Transgenomic*, Glasgow, UK (formerly Cruachem). *Transgenomic is no longer supplying custom oligonucleotides.
The b-gal expression plasmid pCMVb (BD Biosciences Clontech, Oxford, UK) and the luciferase plasmid pVR1223 (Vical, San Diego, USA) were used as controls for transfection efficiency.
In vitro transfection
Transfection complexes were prepared by incubating 5 ml lipofectamine (Invitrogen) per mg DNA diluted in Optimem (Invitrogen) for 30 min. Chromosomal gene repair was achieved in cells at 60-70% confluency with 1 mg of DNA per 3.5 cm plate. Cells were incubated with transfection complex for 5 h, after which they were washed with PBS and the medium replaced with fresh complete medium. Cells were assayed for transfection efficiency 48 h post-transfection.
In vivo gene delivery
Intraperitoneal injections were performed on neonatal or 4-week-old mice. For intraperitoneal and intravenous delivery, oligonucleotides or chimaeraplasts were either delivered uncomplexed in PBS or incubated in 5% dextrose with ExGen 500 (TCS, Buckingham, UK) or JETPEIGal (Polyplus transfection, Illkirch Cedex, France) at a 10:1 amine:phosphate ratio for 15 min prior to injection. Mice were generally dosed in groups of six. Neonates received 5-50 mg oligonucleotide, adults received 50-200 mg. Intravenous injections were performed with a 27.5 gauge needle, on Avertin anaesthetized mice of 6-8 weeks, via the lateral tail vein. Mice were kept warm and monitored until recovery on a heat pad.
Intramuscular injections were performed using the PE6400 reagent. 36 DNA (50 mg) per muscle was complexed with PE6400 at a final concentration of 0.1% in 150 mM NaCl. Mice were anaesthetized with Avertin and injected longitudinally in the anterior tibialis muscle. Mice were kept warm and monitored until recovery on a heat pad. After 7 days, the whole of the anterior tibialis muscle was removed for X-gal staining to ensure that the site of injection was not missed.
Detection of gene delivery and gene repair X-Gal stain was prepared by adding 1 mg/ml Xgal solution (prepared as 25 mg/ml stock in dimethyl formamide) into X-Gal staining solution (PBS with 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 , pH adjusted to between 7.5 and 8.0) pre-warmed to 371C. Cells were washed in PBS, fixed for 10 min in 4% paraformaldehye in PBS and, after a further PBS wash, stained overnight at 371C.
Tissues were either cryosectioned, or fixed in 4% paraformaldehyde/PBS prior to whole-mount staining. Sections of unfixed liver, frozen in Tissue-Tek optimum cutting temperature (OCT) compound (Sakura), were cut at 10-30 mm at À161C onto Superfrost-coated slides (BDH), air dried and stored at À701C. For staining, slides were rehydrated for 5 min in PBS, fixed for 10 min in ice-cold methanol, rehydrated for 10 min in PBS and immersed in X-Gal stain for 6 h or overnight at 371C. Slides were washed for 5 min in PBS, post-fixed in 4% paraformaldehyde/PBS for 10 min, and rehydrated for 5 min in PBS. Slides were counterstained in 0.01% safranin. For whole-mount staining, mice were killed by CO 2 asphyxiation and perfused via the heart with 20 ml PBS to remove excess blood from organs. Organs were carefully dissected and fixed in 4% paraformaldehyde/PBS at 41C for 2 h. Organs were then washed for 3 Â 30 min in rinse buffer (PBS with 2 mM MgCl 2 , 0.1% Triton X-100) prior to overnight X-gal staining as above.
LacZ-based mouse for detection of gene repair events HD Nickerson and WH Colledge
